Eczema molluscatum in tacrolimus treated atopic dermatitis

Eur J Dermatol. 2004 Jan-Feb;14(1):73-4.

Abstract

Eczema molluscatum describes the occurrence of molluscum contagiosum virus infection in a patient with underlying atopic dermatitis. Novel, safe and effective treatment options in atopic dermatitis are the topical immunomodulators tacrolimus and pimecrolimus. One major advantage over corticosteroids is that they do not induce skin atrophy. Some physicians fear that topical immunomodulators may predispose patients to skin infections. We observed a patient with atopic dermatitis who developed eczema molluscatum during treatment with tacrolimus 0.1% ointment. After withdrawal of tacrolimus, the lesions resolved spontaneously over 3 weeks.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Dermatitis, Atopic / diagnosis
  • Dermatitis, Atopic / drug therapy*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Eczema / chemically induced*
  • Eczema / diagnosis
  • Follow-Up Studies
  • Humans
  • Male
  • Molluscum Contagiosum / chemically induced*
  • Molluscum Contagiosum / diagnosis
  • Risk Assessment
  • Skin Diseases, Viral / diagnosis
  • Tacrolimus / adverse effects*
  • Tacrolimus / therapeutic use

Substances

  • Tacrolimus